Behavioral factors, fragmented care, and systemic barriers disproportionately impact obesity patients, making long-term adherence difficult
The five qualifying conditions The five qualifying conditions for the NHS pathway under NICE TA1026 are 4 : Type 2 diabetes High blood pressure (hypertension) Cardiovascular disease (previous heart attack, stroke, angina, or coronary procedure) High cholesterol or dyslipidaemia Obstructive sleep apnoea For the private route, the Mounjaro and Wegovy product licences accept any one of these, plus prediabetes (an HbA1c blood-sugar reading between 42 and 47 mmol/mol) 1,2
Furthermore, GLP-1 RAs play a pivotal role in the alleviation of oxidative stress, the maintenance of mitochondrial homeostasis, and the inhibition of cell apoptosis and pyroptosis in models of ischemic cardiomyopathy [16]
In SUSTAIN 6, semaglutide was associated with an increased rate of diabetic retinopathy complications, largely explained by the magnitude and speed of HbA1c reduction in people with existing retinopathy and poor baseline control, often on insulin
Below are some details of the pharmacology of the medication that makes it such an effective weight-loss drug: GLP-1s stimulate the secretion of insulin and slow the release of glucagon, thereby keeping blood sugar low
Remember that these foods still need to be eaten in moderation, like any other food, as they are higher in calories